Source:http://linkedlifedata.com/resource/pubmed/id/21512310
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2011-4-22
|
pubmed:abstractText |
Osteopontin (OPN) is overexpressed in a variety of cancers including hepatocellular carcinoma (HCC), and is likely involved in the process of vasculogenic mimicry (VM) in some tumor cells. In this study, we explored whether OPN plays a role for VM in HCC. Metastatic MHCC97-H human HCC cells and non-metastatic Hep3B human HCC cells were compared for their abilities to establish VM. Three dimensional-culture assays showed that MHCC97-H cells but not Hep3B cells were able to form the chord-like structure that represents VM. Real-time RT-PCR arrays were used to detect gene expression profiles of the two HCC cell lines in three-dimensional culture. PCR array analyses revealed the increased expression of OPN in MHCC97-H cells forming VM compared with Hep3B cells. Small interfering RNA was employed to investigate whether OPN knockdown could influence VM, and the expression of matrix metalloproteinase (MMP)-2, MMP-9 and urokinase-type plasminogen activator (uPA) in MHCC97-H cells. OPN knockdown resulted in a significant decrease in the ability of MHCC97-H cells to form VM, which was accompanied by the down-regulation of MMP-2 and uPA expression. Furthermore, human HCC tissue samples were studied by immunohistochemistry to analyze the correlations between VM and the expression of OPN, MMP-2 and uPA. There existed significant positive correlations between VM and the expression of OPN, MMP-2 and uPA in HCC tissue samples. In conclusion, OPN is required for VM in HCC cells, and its action may be associated with activation of MMP-2 and uPA. OPN-targeted therapeutics may be useful for patients with advanced HCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 9,
http://linkedlifedata.com/resource/pubmed/chemical/Osteopontin,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/Urokinase-Type Plasminogen Activator
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1349-3329
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
224
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
29-39
|
pubmed:meshHeading |
pubmed-meshheading:21512310-Carcinoma, Hepatocellular,
pubmed-meshheading:21512310-Cell Line, Tumor,
pubmed-meshheading:21512310-DNA Primers,
pubmed-meshheading:21512310-Gene Expression Profiling,
pubmed-meshheading:21512310-Gene Knockdown Techniques,
pubmed-meshheading:21512310-Humans,
pubmed-meshheading:21512310-Immunohistochemistry,
pubmed-meshheading:21512310-Liver Neoplasms,
pubmed-meshheading:21512310-Matrix Metalloproteinase 2,
pubmed-meshheading:21512310-Matrix Metalloproteinase 9,
pubmed-meshheading:21512310-Neovascularization, Pathologic,
pubmed-meshheading:21512310-Osteopontin,
pubmed-meshheading:21512310-RNA, Small Interfering,
pubmed-meshheading:21512310-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:21512310-Urokinase-Type Plasminogen Activator
|
pubmed:year |
2011
|
pubmed:articleTitle |
Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma.
|
pubmed:affiliation |
Centre for the Study of Liver Cancer and Department of Hepatic Surgery, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, PR China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|